Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07140744 · ClinicalTrials.gov registry record · NA
A Study Evaluating the Impact of P-tau217 Blood Biomarker Testing on Early Evaluation and Management of Patients Presenting With Cognitive Complaint
A NA study of Subjective Cognitive Impairment, sponsored by Eli Lilly and Company.
- Recruiting
- Registry status
- NA
- Development phase
- 7,000
- Enrollment target
- 1
- Study location
NCT07140744: Recruiting NA study of Subjective Cognitive Impairment, sponsored by Eli Lilly and Company.
NCT07140744 is a NA study of Subjective Cognitive Impairment that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 7,000 participants, above the 1,403-participant average among 58,714 other NA trials with a reported enrollment target (399% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07140744, a NA study of Subjective Cognitive Impairment, is actively recruiting participants, sponsored by Eli Lilly and Company.
- RECRUITING
- Registry status
- NA
- Development phase
- 7,000 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to measure the difference in the proportion of participants with prespecified patient management actions between a tested interventional group and a control group.
Primary Outcome
Difference in proportion of participants with a least 1 management action, referral to Secondary or Tertiary Care Physician (S/TCP); counseling; Alzheimer's Disease (AD) drug therapy related to cognitive complaint, or Non-AD drug therapy related to cognitive complaint.
Conditions Studied
Interventions
- OTHER Standard of Care
- DIAGNOSTIC_TEST P-tau217
Study Locations (1)
New York
- SiteRx Virtual Site - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7,000 participants |
| Start Date | 2025-08-22 |
| Est. Completion | 2027-10 |
| Phase | NA |
What NCT07140744 shows while recruiting
NCT07140744 is an interventional study that assigns participants to a tested intervention. Its 7,000 participants enrollment target places it among the larger protocols in the corpus, above the 1,403-participant average among 58,714 other NA trials with a reported enrollment target (399% higher).
The record links to 1 condition, with Subjective Cognitive Impairment appearing as the primary indexed condition, and to 2 interventions - of which Standard of Care is the first listed.
NCT07140744 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT07140744 about?
NCT07140744 is a clinical study titled "A Study Evaluating the Impact of P-tau217 Blood Biomarker Testing on Early Evaluation and Management of Patients Presenting With Cognitive Complaint". The purpose of the study is to measure the difference in the proportion of participants with prespecified patient management actions between a tested interventional group and a control group.
What is the current status of trial NCT07140744?
This trial is currently recruiting. It is a NA study. The enrollment target is 7,000 participants. The study started on 2025-08-22. Estimated completion is 2027-10.
What conditions does trial NCT07140744 study?
This clinical trial studies the following conditions: Subjective Cognitive Impairment.
What interventions are being tested in trial NCT07140744?
The interventions under investigation include: Standard of Care (OTHER), P-tau217 (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT07140744?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07140744 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Subjective Cognitive Impairment
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07140744's enrollment target sits among peer trials
7,000 21st of 2000 higher than 1,980 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00260585 · 7,000 participants
Esophageal Cancer Risk Registry
- NCT04118660 · 7,000 participants
Thoracic Specimen Registry
- NCT07106879 · 7,000 participants
Non-interventional Pre-screening Protocol Aims to Evaluate Participants for Potential Trial Eligibility in Future Clinical Trials/Studies Focusing on Metabolic and Psychiatric Health.
- NCT06843720 · 7,100 participants · NA
Expanding Access to Cervical Cancer Screening Through Primary HR-HPV Testing and Self-sampling: a Multicomponent Intervention for Safety Net Health Systems
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI